Table 2 Agents targeting CSC-associated surface markers in ongoing clinical trials

 Catumaxomabr (emovab)

EpCAM/CD3

Ovarian cancer

II

44

NCT00189345

Completed

 Tagraxofusp

  SL-401

CD123

Acute myeloid leukemia

I

36

NCT03113643

Recruiting

 KHK2823

I

39

NCT02181699

Terminated

 Talacotuzumab

III

326

NCT02472145

Completed, has results

 SGN-CD123A

I

17

NCT02848248

Terminated

 IMGN632

II

155

NCT03386513

Recruiting

 XmAb14045

CD123/CD4

II

105

NCT02730312

Recruiting

 MGD006

CD123/CD3

II

179

NCT02152956

Recruiting

 JNJ-63709178

III

326

NCT02472145

Completed, has results

 CSL362

CD124

I

30

NCT01632852

Completed

 TTI-621

CD47

Solid tumor

I

260

NCT02663518

Recruiting

 Hu5F9-G4

Solid tumor

I

88

NCT02216409

Completed

 IBI188

Advanced malignancies

I

42

NCT03763149

Recruiting

 CC-90002

Hematologic neoplasms

I

28

NCT02641002

Terminated

 AO-176

Solid tumor

I

90

NCT03834948

Recruiting

 SRF231

Solid tumor

I

148

NCT03512340

Recruiting

 Bivatuzumab mertansine

Metastatic breast cancer

I

24

NCT02254005

Completed

 Vadastuximab talirine (SGN-CD33A)

CD33

Acute myelogenous leukemia

I

195

NCT01902329

Completed

 IMGN779

I

62

NCT02674763

Completed

 Mylotarg (gemtuzumab ozogamicin)

ECG

IV

56

NCT03727750

Recruiting

 RO5429083

CD44

Malignant solid tumors

I

65

NCT01358903

Completed

 SPL-108

Ovarian cancer

I

18

NCT03078400

Recruiting

 Salazosulfapyridine

CD44V4

Non-small-cell lung cancer

I

UMIN000017854

 AMC303

CD44V6

Solid tumor

I

55

NCT03009214

Recruiting

 Ipilimumab

CTLA-4

Non-small-cell lung cancer

II

24

NCT01820754

Completed, has results

 Nivolumab

PD-1

Glioblastoma multiforme

II

29

NCT02550249

Completed

 Pembrolizumab

II

80

NCT02337491

Completed, has results

 Cemiplimab

II

30

NCT04006119

Recruiting

 Idarubicin

Acute myeloid leukemia

II

51

NCT01035502

Completed

 Sym021

Solid tumor lymphomas

I

102

NCT03311412

Recruiting

 Durvalumab

Solid tumors

II

124

NCT02403271

Completed, has results

 Atezolizumab

PD-L1

Non-small-cell lung cancer

III

1225

NCT02008227

Completed, has results

 Avelumab

Recurrent glioblastoma

II

52

NCT03291314

Completed

 Sym023

Tim3

Solid tumor

I

48

NCT03489343

Recruiting

 ARGX-110

CD70

Acute myeloid leukemia

II

36

NCT03030612

Active, not recruiting

 Varlilumab (CDX-1127)

Solid tumors

II

175

NCT02335918

Completed

 Sym022

LAG3

Solid tumor

I

30

NCT03489369

Recruiting

 MGD013

CD70/LAG3

Solid tumors

I

255

NCT03219268

Recruiting